This is also in agreement with CRC CD133+CXCR4+ CRC cells displaying CSC and MetSC capacities, whereas CD133+ CXCR4− cells have only CSC capacity (Zhang et al, 2012), which further supports the notion that T22‐GFP‐H6‐FdU selectively targets the subset of CXCR4+ MetSCs rather than CSCs. The gene discussed is CXCR4; the disease is colorectal carcinoma.